PDPL

Trading in the equity shares of Parenteral Drugs (India) Limited (PDPL) shall remain suspended pursuant to intimation received from the Company. As per Resolution Plan the existing equity shares of the Company shall stand delisted with Nil payment. For the detailed corporate announcement submitted by the Company please refer the Exchange website.

PDPL:The Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to announcement dated 02-Feb-2022, regarding appointment of Director and Company secretary in the Board meeting held on February 02, 2022. On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment2. Brief profile (in case of appointment)3. Whether intimated in 24hrs4. Affirmationﾠthat the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority

Significant movement in price has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has submitted their response.

Significant movement in price has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

PDPL: The Exchange had sought clarification from Parenteral Drugs (India) Limited with respect to announcement dated 14-Nov-2016, regarding "Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of

PDPL:The Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to announcement dated 14-Nov-2016, regarding "Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of

Parenteral Drugs (India) Limited has submitted to the Exchange a Clarification on Outcome of Board Meeting held on November 9, 2015.

Clarification by Parenteral Drugs (India) LimitedSignificant price movement has been observed in Parenteral Drugs (India) Limited.The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Parenteral Drugs (India) Limitedhas vide its letter inter-alia stated, "accordingly to clause 36 of the Listing agreement the company does not have any information which is required to be informed to the exchange and members that have a bearing on the operati

Price movement : Significant price movement has been observed in Parenteral Drugs (India) Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has vide its letter inter-alia stated,"The present situation in the prices of the shares of the Company is due to the market forces and not because of the reason known to the management of the Company, as the Promoters of the Company are not trading in th

Price movement : Significant price movement has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has vide its letter inter-alia stated, "We would like to submit that with regard to the perfomance of the Company and internal price sensitive factors (which do not include any change in Govt. policies), the same are being submitted to you from time to tim